Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$297.39
-2.6%
$326.76
$202.99
▼
$382.54
$8.81B0.56325,848 shs102,643 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$19.47
-3.4%
$21.53
$17.90
▼
$42.21
$2.33B0.151.20 million shs1.42 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$124.23
-5.1%
$140.30
$77.00
▼
$160.81
$8.11B1.21709,695 shs305,076 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.30
-6.7%
$96.88
$74.50
▼
$122.20
$7.44B2.17853,043 shs667,222 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+1.45%-3.59%-9.08%+48.05%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+6.56%+1.56%-25.13%-47.48%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%-0.83%+1.71%-17.44%+54.77%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+2.44%+33.48%-0.36%+15.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$297.39
-2.6%
$326.76
$202.99
▼
$382.54
$8.81B0.56325,848 shs102,643 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$19.47
-3.4%
$21.53
$17.90
▼
$42.21
$2.33B0.151.20 million shs1.42 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$124.23
-5.1%
$140.30
$77.00
▼
$160.81
$8.11B1.21709,695 shs305,076 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.30
-6.7%
$96.88
$74.50
▼
$122.20
$7.44B2.17853,043 shs667,222 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+1.45%-3.59%-9.08%+48.05%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+6.56%+1.56%-25.13%-47.48%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%-0.83%+1.71%-17.44%+54.77%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+2.44%+33.48%-0.36%+15.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.93
Moderate Buy$375.0024.13% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.83
Moderate Buy$49.82144.99% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.06
Buy$166.6729.60% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.77
Moderate Buy$142.0029.54% Upside

Current Analyst Ratings Breakdown

Latest NAMS, KRYS, PTGX, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Boost Price TargetOverweight$52.00 ➝ $61.00
11/9/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Reiterated RatingOutperform
11/6/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Boost Price TargetBuy$170.00 ➝ $221.00
11/6/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetOverweight$145.00 ➝ $142.00
11/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Lower Price TargetBuy$48.00 ➝ $46.00
11/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetBuy$143.00 ➝ $147.00
11/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
DowngradeBuy (B) ➝ Buy (B-)
11/4/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
UpgradeHold (C+) ➝ Buy (B-)
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingMarket Perform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingOutperform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetMarket Outperform$160.00 ➝ $166.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M23.00$7.22 per share41.87$42.06 per share7.18
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$25.94M94.03N/AN/A$5.97 per share3.41
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M182.40N/AN/A$9.83 per share13.08
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M40.05N/AN/A$2.08 per share52.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.3740.9833.91N/A47.91%17.02%15.48%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$1.69N/AN/AN/A-789.95%-31.39%-28.32%N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$4.7227.2896.70N/A62.04%42.83%40.29%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$2.90N/AN/AN/A-69.03%-171.16%-43.00%N/A

Latest NAMS, KRYS, PTGX, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.50$3.07+$0.57$3.07$238.49 million$274.41 million
11/4/2026Q3 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4718-$0.14+$0.3318-$0.14$8.82 million$19.16 million
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7097-$0.61+$0.0997-$0.61$85.56 million$92.13 million
11/2/2026Q3 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.79$2.05+$0.26$2.05$125.77 million$127.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
7.89
7.53
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
11.76
11.76
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
19.85
19.85
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.78
2.57

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
29529.63 million25.75 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.93 million104.65 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
14165.27 million61.88 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41469.33 million65.24 millionOptionable

Recent News About These Companies

Rhythm Pharmaceuticals Earnings Call Signals Strong Growth Ahead

New MarketBeat Followers Over Time

Media Sentiment Over Time

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$297.39 -7.84 (-2.57%)
Closing price 03:59 PM Eastern
Extended Trading
$297.90 +0.51 (+0.17%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$19.46 -0.68 (-3.35%)
Closing price 03:59 PM Eastern
Extended Trading
$19.46 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$124.23 -6.72 (-5.13%)
Closing price 03:59 PM Eastern
Extended Trading
$124.50 +0.27 (+0.22%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$107.30 -7.72 (-6.71%)
Closing price 03:59 PM Eastern
Extended Trading
$107.40 +0.10 (+0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.